There are a number of reasons why once-daily Tresiba® may be the right option for your appropriate patients with diabetes starting on or switching to basal insulin, including a slow and steady release and a long duration of action.1-3
The Tresiba® molecule is different by design
A flat, stable profile
Tresiba® U-100 concentrations remained stable from day to day at steady state1-3


Values are estimated ratios relative to day 10; clinical steady state is defined as >90% of the final plateau level.2
- The recommended time between dose increases is 3 to 4 days (the same amount of time it takes to reach steady state)1

The basal insulin that gives adult patients the option to change day-to-day dose timing if needed1

Tresiba® U-100 is the only basal insulin proven to last 42 hours—that won’t taper off at the end of the day1,5-8,a
A consistent routine is important, but if life gets in the way of a scheduled dose, Tresiba® provides continued efficacy.1
- Tresiba® was studied at alternating once-daily dosing intervals of 8 to 40 hours in adult patients1
- Adult patients who miss a dose of Tresiba® should inject their daily dose during waking hours upon discovering the missed dose, then continue with their regular dosing schedule1
- Adult patients should wait at least 8 hours between Tresiba® injections1

Less within-subject variability for patients on Tresiba®

Less within-subject variability for patients on Tresiba®
ONE DOSING INTERVAL
Tresiba® U-100 had 4X less within-subject, day-to-day variability vs insulin glargine U-1003
Calculated using the glucose infusion rate (GIR) profiles of adults with type 1 diabetes (P<0.0001)
One dosing interval (0-24 h) at steady state


The clinical significance of these PK/PD differences has not been established
IN A POST HOC ANALYSIS
Tresiba® U-100 had less within-subject, day-to-day variability when evaluated every 2 hours vs insulin glargine U-1003
Calculated using the glucose infusion rate (GIR) profiles of adults with type 1 diabetes (P<0.0001)
2-hour intervals at steady state over the course of 24 hours


The clinical significance of these PK/PD differences has not been established
Tresiba® has the longest half-life of any basal insulin1,7,9,10,b
Tresiba®

Insulin glargine U-100





bThe mean half-life of other basal insulins: insulin glargine U-300: 19 hours5; insulin detemir: 5 to 7 hours depending on dose6; NPH: 4.4 hours.10
c13.5-hour half-life for insulin glargine U-100 is based on 0.4 units/kg dose.
Study designs
The Heise, Hermanski, et al Study3
Population: Adults with type 1 diabetes.
Study design: Randomized, double-blind, parallel-group, single-center trial evaluating the within-subject, day-to-day variability and glucose-lowering effect of Tresiba® U-100 (n=27) vs insulin glargine U-100 (n=27) under steady-state conditions. Patients received Tresiba® U-100 or insulin glargine U-100 (0.4 units/kg) once daily for 12 days. The euglycemic clamp was performed on days 6, 9, and 12 of treatment and blood samples were taken throughout each clamp period.
Primary endpoint: To evaluate the within-subject variability of the PD response between Tresiba® U-100 and insulin glargine U-100 based on the area under the glucose infusion rate curve (AUCGIR) during 1 dosing interval (0-24 hours) at steady state. The within-subject, day-to-day PD variability in glucose-lowering effect in the Tresiba® arm was 20% and in the insulin glargine U-100 arm was 82% at steady state.
Secondary PD endpoints: To investigate whether within-subject variability was consistent over 24 hours, the within-subject of AUCGIR in 2-hour intervals (AUCGIR,0-2h,SS' AUCGIR,0-2h,SS' AUCGIR,20-22h,SS' AUCGIR,22-24h,SS) was analyzed in a post-hoc analysis.
The Heise, Korsatko, et al Study2
Population: Adults with type 1 diabetes or type 2 diabetes.
Study design: Post hoc analysis of 5 randomized, double-blind, single-center, phase 1 trials. Patients (n=195) received once-daily doses ranging from 0.4-0.8 U/kg and for 6-12 days, depending on the individual study.
Primary endpoint: Determining the duration and consistency of time to steady state Tresiba® U-100 following once-daily subcutaneous dosing in subjects of varying age and diabetes type.
AUCGIR,0-24h,SS=area under the GIR curve from 0 to 24 hours at steady state; CV=coefficient of variation; PK/PD=pharmacokinetic/pharmacodynamics.